Wyss Center for Bio and Neuroengineering

Safer and more Effective Brain Interfaces: First in Human Brain Recordings Achieved by Neurosoft Bioelectronics

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Health, Medical Devices, Neurology, Health Technology, Clinical Trials, Biotechnology, Epilepsy, Swiss, Swiss Federal Institute of Technology, Digital Writing and Research Lab, Tinnitus, Deafness, Auditory cortex, Brain, Multimedia, Research, Biomarker, Trial of the century, Paralysis, DSM-IV codes, Wyss Center for Bio and Neuroengineering, Electrode, Patient, Traumatic brain injury, Memorial Hermann Health System, Hematoma, EPFL, FDA, Swiss Federal Institute of Aquatic Science and Technology, Safety, Hippocampus, Medical imaging, Medical device, Nursing

Two epileptic patients and one brain tumour patient have undergone a successful surgery, while detailed recordings were obtained in parallel from the surface of the brain.

Key Points: 
  • Two epileptic patients and one brain tumour patient have undergone a successful surgery, while detailed recordings were obtained in parallel from the surface of the brain.
  • Furthermore, the application of Neurosoft Bioelectronics’ electrodes presents the possibility of uncovering supplementary biomarkers which could significantly help in providing more effective and safer treatments of brain disorders for future patients.
  • Amidst these challenges, Neurosoft Bioelectronics' soft and elastic electrodes present themselves as a promising alternative to existing invasive solutions.
  • The Neurosoft Bioelectronics team has also been studying how these electrodes could address indications like severe tinnitus.

Wyss Center Appoints Dr. Craig Cook as New Head of Business Development and Licensing

Retrieved on: 
Monday, July 10, 2023
Other Health, Research, General Health, Philanthropy, Mental Health, Health Technology, Science, Biotechnology, Neurology, Other Philanthropy, Other Science, Health, Business development, Brain, Head, Pediatrics, London Business School, Molina Healthcare, Wyss Center for Bio and Neuroengineering, Longevity, MBA, Multimedia, University of the Witwatersrand, CNS, Translation, Eli Lilly, Bachelor of Science, Anesthesia, Neurotechnology, Medicine, Neuroscience, King's College London, Translational medicine, Novartis, MD, Master of Science, Wyss, Medtech, Mental health, Pharmaceutical industry, Anesthesiology, Serono, Pharmacology

The Wyss Center, a leading non-profit research center dedicated to innovating and accelerating technologies and therapies for neurological and mental health disorders, is pleased to announce the appointment of Craig Cook, MD, MBA, to the leadership team as Head of Business Development and Licensing.

Key Points: 
  • The Wyss Center, a leading non-profit research center dedicated to innovating and accelerating technologies and therapies for neurological and mental health disorders, is pleased to announce the appointment of Craig Cook, MD, MBA, to the leadership team as Head of Business Development and Licensing.
  • Dr. Cook brings more than 25 years of impressive executive leadership and entrepreneurial expertise in the fields of biotech, medtech and clinical medicine.
  • View the full release here: https://www.businesswire.com/news/home/20230710043091/en/
    “The addition of Craig to the Wyss Center team comes at a pivotal time,” said Erwin Bottinger, MD, CEO of the Wyss Center, “Craig brings a wealth of experience in translating medical technologies and therapies into clinical impact.
  • Dr. Cook's extensive track record complements the Wyss Center's commitment to neurological and mental health, strengthening its science and technology portfolio.

Wyss Center Geneva Appoints Erwin Böttinger as new Chief Executive Officer

Retrieved on: 
Monday, April 3, 2023
Mental Health, Technology, Medical Devices, Neurology, Biometrics, Other Health, Biotechnology, Health, Oncology, Artificial Intelligence, Monochorionic twins, Wyss Foundation, Hasso Plattner Institute, Berlin Institute for Advanced Study, Broad Institute, University, Wyss Center for Bio and Neuroengineering, Icahn School of Medicine at Mount Sinai, Bio, Multimedia, Research, Genomics, Mount Sinai, Translation, University of Geneva, Campus Biotech, DSM-IV codes, Digital health, MD, RTÉ Executive Board, Artificial intelligence, Psychiatry, CHF, Stanley Center for Psychiatric Research at Broad Institute, Geneva University Hospitals, Management, Pharmaceutical industry

The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med.

Key Points: 
  • The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med.
  • Erwin Böttinger as its new Chief Executive Officer (CEO).
  • Erwin Böttinger, Chief Executive Officer of the Wyss Center for Bio and Neuroengineering.
  • Since its founding, the Wyss Center has developed strong systems to advance vital technologies to the clinic.

S3 Connected Health Receives Frost & Sullivan's Award for Helping Medical Device Companies Create Custom Connected Medical Device Solutions

Retrieved on: 
Wednesday, November 30, 2022
Cloud, IEC, Health Insurance Portability and Accountability Act, SAN, Vittal, Internet, Connected health, Health, Accountability Act, Neurology, General Data Protection Regulation, MDC, GDPR, Wyss Center for Bio and Neuroengineering, Cochlear nucleus, Research, HIPAA, Costruzioni Italiane Serrature e Affini, ISO, Cardiology, Safety, Risk management, Medical device

SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- Recently, Frost & Sullivan analyzed the global medical device connectivity industry and, based on its research findings, recognizes S3 Connected Health with the 2022 Global Customer Value Leadership Award for medical device connectivity. The company has broad expertise in wireless connectivity, software development, software-as-a-medical-device (SaMD), Internet of Medical Things (IoMT), medical device regulations, and data security. The company's connected medical devices and digital health solutions meet stringent global regulatory standards, including ISO, IEC, Health Insurance Portability and Accountability Act (HIPAA), and General Data Protection Regulation (GDPR), for medical device development, performance, and safety.

Key Points: 
  • Get access to more details on S3 Connected Health's awards page:
    S3 Connected Health is a preferred digital health partner for medical device companies based on its ability to create custom solutions, including connected medical devices and digital health applications enabled by the Affinial digital health platform.
  • In addition, the company ensures the seamless integration of all components, such as devices, applications, and third-party information systems.
  • Quality, ease of interaction with management and engineering teams, and continuous support post-project implementation are S3 Connected Health's primary advantages as a partner.
  • With its strong overall performance, S3 Connected Health earns Frost & Sullivan's 2022 Global Customer Value Leadership Award in the medical device connectivity industry.

S3 Connected Health Receives Frost & Sullivan's Award for Helping Medical Device Companies Create Custom Connected Medical Device Solutions

Retrieved on: 
Wednesday, November 30, 2022
Cloud, IEC, Health Insurance Portability and Accountability Act, SAN, Vittal, Internet, Connected health, Health, Accountability Act, Neurology, General Data Protection Regulation, MDC, GDPR, Wyss Center for Bio and Neuroengineering, Cochlear nucleus, Research, HIPAA, Costruzioni Italiane Serrature e Affini, ISO, Cardiology, Safety, Risk management, Medical device

SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- Recently, Frost & Sullivan analyzed the global medical device connectivity industry and, based on its research findings, recognizes S3 Connected Health with the 2022 Global Customer Value Leadership Award for medical device connectivity. The company has broad expertise in wireless connectivity, software development, software-as-a-medical-device (SaMD), Internet of Medical Things (IoMT), medical device regulations, and data security. The company's connected medical devices and digital health solutions meet stringent global regulatory standards, including ISO, IEC, Health Insurance Portability and Accountability Act (HIPAA), and General Data Protection Regulation (GDPR), for medical device development, performance, and safety.

Key Points: 
  • Get access to more details on S3 Connected Health's awards page:
    S3 Connected Health is a preferred digital health partner for medical device companies based on its ability to create custom solutions, including connected medical devices and digital health applications enabled by the Affinial digital health platform.
  • In addition, the company ensures the seamless integration of all components, such as devices, applications, and third-party information systems.
  • Quality, ease of interaction with management and engineering teams, and continuous support post-project implementation are S3 Connected Health's primary advantages as a partner.
  • With its strong overall performance, S3 Connected Health earns Frost & Sullivan's 2022 Global Customer Value Leadership Award in the medical device connectivity industry.

Wyss Center for Bio and Neuroengineering: New Horizons in Neural Recording Systems

Retrieved on: 
Thursday, October 13, 2022
Other Health, Research, Radiology, Medical Devices, Technology, Clinical Trials, Science, Biotechnology, Neurology, Other Technology, Other Science, Health, Quality of life, Method, Caregiver, Wyss Center for Bio and Neuroengineering, Interface (computing), Bio, Communication, Patient, Amyotrophic lateral sclerosis, MBA, Research, ALS, Multimedia, Technology, Trial of the century, Doctor of Philosophy, BCI, Brain, Paralysis, Record, Medical device

A new whitepaper, released by the Wyss Center for Bio and Neuroengineering, reveals the first neural signals recorded by the ABILITY brain-computer interface (BCI) system.

Key Points: 
  • A new whitepaper, released by the Wyss Center for Bio and Neuroengineering, reveals the first neural signals recorded by the ABILITY brain-computer interface (BCI) system.
  • Wyss Center
    Jonas Zimmerman , PhD, Senior Neuroscientist at the Wyss Center, explains: Neuroscience is experiencing a global renaissance.
  • says Prof. Nick Ramsey from the UMC Utrecht Brain Center and Wyss Center collaborator.
  • About the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland
    The Wyss Center is an independent, non-profit, research and development organization that advances our understanding of the brain to realize therapies and improve lives.

GliaPharm SA and the Wyss Center Enter Collaboration to Develop New Therapies for Alzheimer’s Disease

Retrieved on: 
Thursday, February 24, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Genetics, Clinical Trials, Wyss Center for Bio and Neuroengineering, Lists of diseases, Glucose, Comparison, École Polytechnique, Campus Biotech, Glucose transporter, Drug development, EPFL, Disease, Bio, Neuron, Alzheimer's disease, Biomarker, Neurodegeneration, Brain, Neuroimaging, Wyss, Research, Neuroscience, Pharmaceutical industry, Medical imaging, GliaPharm, the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland, GLIAPHARM, THE WYSS CENTER FOR BIO AND NEUROENGINEERING, GENEVA, SWITZERLAND

One of the hallmarks of neurodegenerative diseases such as Alzheimers is reduced glucose uptake by the brain, known as hypometabolism.

Key Points: 
  • One of the hallmarks of neurodegenerative diseases such as Alzheimers is reduced glucose uptake by the brain, known as hypometabolism.
  • The collaboration with the Wyss Center will allow us to accelerate our drug development towards other neurological indications that are linked to brain metabolism dysfunction, such as Alzheimer's disease.
  • GliaPharm will test the impact of its lead candidates in preclinical models of Alzheimers disease to advance the compounds towards clinical stage.
  • The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjrg Wyss in 2014.

Wispr AI Secures $4.6M from NEA and 8VC to Build Thought-Powered Neural Interface

Retrieved on: 
Tuesday, November 30, 2021
CTO, SAIL, Luminous, CEO, Technology, Wyss Center for Bio and Neuroengineering, Deep learning, Brain, Leg, Electromyography, Stanford University centers and institutes, AI, Muscle, WISPr, Health, Human, IPO, International Olympiad in Informatics, SAN, COO, Apple, New Enterprise Associates, Salesforce, IOI, EKG, VR, Machine learning, EMG, Communication, Stanford University, X-Men 2099, Work, Initial public offering, Meta, NEA, ML, Bessemer Venture Partners, Engineering, Ecosystem, Multimedia, Harvard Medical School, OpenGov, Medical imaging, Medical device, Toy

Wispr AI plans to use the funding to accelerate development of the first functional thought-powered digital interface.

Key Points: 
  • Wispr AI plans to use the funding to accelerate development of the first functional thought-powered digital interface.
  • Wispr AI is building a wearable that can convert deliberate thought into action and high-bandwidth digital input.
  • Kothari, CEO of Wispr AI, previously led engineering and product at Cerebra Technologies after founding FeatherX, which Cerebra acquired.
  • "What Wispr AI has already accomplished in the development of its thought-powered digital interface is nothing short of mind-blowing," said Greg Papadopoulos, Venture Partner at NEA.

PathMaker Neurosystems Appoints Leading Neurotechnology Expert, John Donoghue, Ph.D., to Board of Directors

Retrieved on: 
Thursday, October 21, 2021
US Foods, Spasticity, Traumatic brain injury, Technology, National academy, Brown University, ALS, Bio, Founder, Wyss Center for Bio and Neuroengineering, FDA, Engineering, Food, Cerebral palsy, Multiple sclerosis, BrainGate, Federal, NSR, Brain, National Academy of Medicine, Board, Translational neuroscience, Stroke, International Prize (Fyssen Foundation), Amyotrophic lateral sclerosis, Lists of diseases, GLOBE, Department, Director, Paralysis, Bachelor of Engineering, Pharmaceutical industry

BOSTON and PARIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (PathMaker), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, welcomes John Donoghue, Ph.D. to the Companys Board of Directors.

Key Points: 
  • BOSTON and PARIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc. (PathMaker), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, welcomes John Donoghue, Ph.D. to the Companys Board of Directors.
  • We are incredibly pleased that John Donoghue is joining PathMakers Board of Directors, said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker.
  • PathMaker has made strong progress and is nearing launch of their first product.
  • I am delighted to be joining the Board of Directors at such a significant time, commented Dr. Donoghue.

Wyss Center Announces CE Mark for Its Brain Data Visualization Software, Epios Cloud

Retrieved on: 
Wednesday, September 29, 2021
Data Management, Biotechnology, Technology, Other Health, Health, General Health, Radiology, Other Technology, Medical Devices, Software, Internet, Cloud, EEG, Safety, Artificial intelligence, Review, Epilepsy, Heart rate, Diagnosis, Health, Stroke, IEC, Software, Multimedia, Patient, Scalp, Bio, Wyss Center for Bio and Neuroengineering, IEC 62304, Rehabilitation, Life, Neuroimaging, Medical device, Disease, Neuroscience, Wyss, CE, Algorithm, MBA, Research, Brain, Movement, Doctor of Philosophy, Web browser, Seizure, Medical imaging, Hospital

The Wyss Center announced today the CE (Conformit Europenne) mark Class I medical device for its Epios Cloud software.

Key Points: 
  • The Wyss Center announced today the CE (Conformit Europenne) mark Class I medical device for its Epios Cloud software.
  • View the full release here: https://www.businesswire.com/news/home/20210929005365/en/
    Epios Cloud is a web-based application for online storage, processing and review of neural signals, including ultra-long-term data.
  • Epios Cloud allows us to synchronize neural data with heart rate or movement information over months or years.
  • The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjrg Wyss in 2014.